Needham analyst Serge Belanger maintained a Hold rating on Zynerba Pharmaceuticals (ZYNE – Research Report) today. The company's shares closed last Monday at $0.89, close to its 52-week low of $0.84. According to TipRanks.com, Belanger is a 1-star analyst with an average return of -1.1% and a 39.9% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical. Zynerba Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
https://www.tipranks.com/news/blurbs/needham-remains-a-hold-on-zynerba-pharmaceuticals-zyne?utm_source=advfn.com&utm_medium=referral
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Zynerba Pharmaceuticals Charts.
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Zynerba Pharmaceuticals Charts.